# Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

> **NCT01769378** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 300 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Placebo
- **DRUG:** Dulaglutide
- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT01769378
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2016-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01769378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01769378, "Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01769378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*